Covered recipient · General Payments record
JORGE TOMAS CASO
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$11.57
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $11.57 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $11.57 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JORGE TOMAS CASO
NPI 1457308157 · CMS profile ID 201338
Allopathic & Osteopathic Physicians / Family Medicine
MIAMI, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $11.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | $11.57 | 09/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738478165 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2022, 2023, 2024, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $5,513,175.40 | 309 |
| PY2024 | Recipient | $2,105.91 | 13 |
| PY2024 | Principal investigator | $5,484,672.89 | 220 |
| PY2023 | Recipient | $1,815.05 | 10 |
| PY2023 | Principal investigator | $6,619,562.71 | 1,445 |
| PY2022 | Principal investigator | $4,761,350.73 | 1,335 |
| PY2021 | Principal investigator | $244,385.00 | 24 |
| PY2019 | Principal investigator | $19,780.00 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
309 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,523.94 | 12/24/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125396 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,523.94 | 12/24/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125416 |
| Principal investigator 1 | ModernaTX, Inc. | $25,990.90 | 12/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968985 |
| Principal investigator 1 | ModernaTX, Inc. | $4,567.68 | 12/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969011 |
| Principal investigator 1 | ModernaTX, Inc. | $819.59 | 12/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969119 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,600.00 | 12/18/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226106052 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,563.00 | 12/12/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196931 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,552.12 | 12/05/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125411 |
| Principal investigator 1 | ModernaTX, Inc. | $200.20 | 12/04/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969005 |
| Principal investigator 1 | ModernaTX, Inc. | $468.00 | 12/04/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969173 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 12/03/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125407 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $500.00 | 12/02/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226106038 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,000.00 | 12/02/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226106044 |
| Principal investigator 1 | ModernaTX, Inc. | $652.06 | 12/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969043 |
| Principal investigator 1 | ModernaTX, Inc. | $6,997.55 | 11/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968993 |
| Principal investigator 1 | ModernaTX, Inc. | $1,629.25 | 11/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968997 |
| Principal investigator 1 | ModernaTX, Inc. | $5,035.68 | 11/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969099 |
| Principal investigator 1 | ModernaTX, Inc. | $1,639.18 | 11/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969115 |
| Principal investigator 1 | ModernaTX, Inc. | $1,964.78 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968961 |
| Principal investigator 1 | ModernaTX, Inc. | $7,593.60 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968965 |
| Principal investigator 1 | ModernaTX, Inc. | $8,038.80 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968967 |
| Principal investigator 1 | ModernaTX, Inc. | $2,522.16 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968971 |
| Principal investigator 1 | ModernaTX, Inc. | $13.17 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969027 |
| Principal investigator 1 | ModernaTX, Inc. | $8,916.18 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969075 |
| Principal investigator 1 | ModernaTX, Inc. | $489.85 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969077 |
| Principal investigator 1 | ModernaTX, Inc. | $3,758.70 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969081 |
| Principal investigator 1 | ModernaTX, Inc. | $3,879.68 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969085 |
| Principal investigator 1 | ModernaTX, Inc. | $1,236.62 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969089 |
| Principal investigator 1 | ModernaTX, Inc. | $2,887.20 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969131 |
| Principal investigator 1 | ModernaTX, Inc. | $3,620.48 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969133 |
| Principal investigator 1 | ModernaTX, Inc. | $64.06 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969135 |
| Principal investigator 1 | ModernaTX, Inc. | $3,388.44 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969137 |
| Principal investigator 1 | ModernaTX, Inc. | $150.66 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969139 |
| Principal investigator 1 | ModernaTX, Inc. | $157.42 | 11/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969141 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,535.58 | 11/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215148 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 11/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968963 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 11/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969083 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 11/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $132.00 | 11/20/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $76.00 | 11/20/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769591 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,523.94 | 11/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125404 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $49,284.88 | 11/17/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226100063 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $24,883.19 | 11/14/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105967 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,038.21 | 11/12/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215302 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,256.30 | 11/12/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100051 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $300.00 | 11/12/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100057 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $351.00 | 11/12/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,575.00 | 11/10/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769593 |
| Principal investigator 1 | Janssen Research & Development, LLC | $726.00 | 11/07/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196178 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 11/05/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969113 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,584.00 | 11/03/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196110 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969127 |
| Principal investigator 1 | ModernaTX, Inc. | $200.20 | 10/29/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969159 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $400.00 | 10/29/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226100089 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100096 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,000.00 | 10/29/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100103 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 10/29/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226106023 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,540.00 | 10/29/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226106034 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $450.00 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,107.50 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769595 |
| Principal investigator 1 | ModernaTX, Inc. | $400.00 | 10/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968983 |
| Principal investigator 1 | ModernaTX, Inc. | $9,449.65 | 10/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969001 |
| Principal investigator 1 | ModernaTX, Inc. | $348.40 | 10/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969071 |
| Principal investigator 1 | ModernaTX, Inc. | $4,661.28 | 10/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969121 |
| Principal investigator 1 | ModernaTX, Inc. | $260.00 | 10/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969125 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $450.00 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100078 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,504.20 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100084 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $650.00 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105988 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,632.35 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105995 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,384.45 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105999 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $200.00 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226106004 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,384.45 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226106011 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,128.15 | 10/27/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226106015 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $30,810.28 | 10/23/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226100073 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,295.00 | 10/22/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215308 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $350.00 | 10/22/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100068 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,888.65 | 10/22/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105976 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $150.00 | 10/22/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105982 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $18,346.50 | 10/17/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105972 |
| Principal investigator 1 | ModernaTX, Inc. | $2,300.00 | 10/16/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969007 |
| Principal investigator 1 | ModernaTX, Inc. | $950.95 | 10/16/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005683 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $79,698.97 | 10/10/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226100047 |
| Principal investigator 1 | ModernaTX, Inc. | $10,766.08 | 10/08/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969105 |
| Principal investigator 1 | Bavarian Nordic A/S | $12,772.13 | 10/03/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215304 |
| Principal investigator 1 | Bavarian Nordic A/S | $300.00 | 10/03/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,642.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,043.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,145.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,500.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12,500.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,945.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $950.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,700.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769585 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,760.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769587 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,500.00 | 10/02/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226100041 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,844.53 | 10/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215300 |
| Principal investigator 1 | ModernaTX, Inc. | $4,305.60 | 09/29/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968999 |
| Principal investigator 1 | ModernaTX, Inc. | $8,472.10 | 09/29/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 09/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $519.48 | 09/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 09/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769565 |
| Principal investigator 1 | Bavarian Nordic A/S | $822.00 | 09/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215298 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,012.00 | 09/19/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175194103 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/17/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968969 |
| Principal investigator 1 | ModernaTX, Inc. | $600.00 | 09/17/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969055 |
| Principal investigator 1 | Janssen Research & Development, LLC | $855.00 | 09/12/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175194275 |
| Principal investigator 1 | Bavarian Nordic A/S | $575.40 | 09/10/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215296 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,400.00 | 09/01/2025 | Non-covered Recipient Entity Suncoast Research Associates | EBSI-CV-317-005 | No dispute reported | 06/30/2026 | 1250214288 |
| Principal investigator 1 | ModernaTX, Inc. | $1,955.10 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968995 |
| Principal investigator 1 | ModernaTX, Inc. | $4,848.48 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969035 |
| Principal investigator 1 | ModernaTX, Inc. | $9,344.34 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969045 |
| Principal investigator 1 | ModernaTX, Inc. | $819.59 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969057 |
| Principal investigator 1 | ModernaTX, Inc. | $335.92 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005677 |
| Principal investigator 1 | ModernaTX, Inc. | $837.32 | 08/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005679 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,022.95 | 08/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 08/27/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769559 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,155.00 | 08/13/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175195616 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $9,700.00 | 08/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185544477 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,744.00 | 08/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215288 |
| Principal investigator 1 | Bavarian Nordic A/S | $9,828.34 | 08/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215292 |
| Principal investigator 1 | Bavarian Nordic A/S | $13,307.69 | 08/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $54.00 | 07/31/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769557 |
| Principal investigator 1 | ModernaTX, Inc. | $326.03 | 07/31/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969053 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/31/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969063 |
| Principal investigator 1 | ModernaTX, Inc. | $1,038.26 | 07/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969003 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969025 |
| Principal investigator 1 | ModernaTX, Inc. | $1,216.80 | 07/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,253.00 | 07/23/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175194197 |
| Principal investigator 1 | ModernaTX, Inc. | $303.75 | 07/16/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969017 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/16/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969019 |
| Principal investigator 1 | ModernaTX, Inc. | $792.00 | 07/09/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005637 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 07/09/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005649 |
| Principal investigator 1 | ModernaTX, Inc. | $3,837.60 | 06/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969037 |
| Principal investigator 1 | ModernaTX, Inc. | $4,236.05 | 06/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969039 |
| Principal investigator 1 | ModernaTX, Inc. | $24,918.24 | 06/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969161 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,080.00 | 06/26/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175195418 |
| Principal investigator 1 | Bavarian Nordic A/S | $746.32 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215280 |
| Principal investigator 1 | ModernaTX, Inc. | $6,000.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968991 |
| Principal investigator 1 | ModernaTX, Inc. | $746.20 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969009 |
| Principal investigator 1 | ModernaTX, Inc. | $4,085.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969097 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969101 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969111 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969149 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 06/25/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 06/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 06/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220769555 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $858.60 | 06/24/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105960 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,000.00 | 06/24/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125392 |
| Principal investigator 1 | Bavarian Nordic A/S | $812.51 | 06/20/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215278 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 06/20/2025 | Non-covered Recipient Entity Suncoast Research Associates LLC Pembroke Pines | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220998405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,904.00 | 06/20/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196368 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,328.18 | 06/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125389 |
| Principal investigator 1 | ModernaTX, Inc. | $28,033.02 | 06/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969051 |
| Principal investigator 1 | ModernaTX, Inc. | $819.59 | 06/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969059 |
| Principal investigator 1 | ModernaTX, Inc. | $11,404.75 | 06/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969123 |
| Principal investigator 1 | ModernaTX, Inc. | $4,118.40 | 06/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969175 |
| Principal investigator 1 | ModernaTX, Inc. | $41,447.34 | 06/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005643 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $388,149.36 | 06/17/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105954 |
| Principal investigator 1 | ModernaTX, Inc. | $20.70 | 06/13/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969201 |
| Principal investigator 1 | ModernaTX, Inc. | $496.80 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969177 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969179 |
| Principal investigator 1 | ModernaTX, Inc. | $82.80 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969181 |
| Principal investigator 1 | ModernaTX, Inc. | $156.01 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969183 |
| Principal investigator 1 | ModernaTX, Inc. | $89,317.84 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969185 |
| Principal investigator 1 | ModernaTX, Inc. | $5,871.65 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969187 |
| Principal investigator 1 | ModernaTX, Inc. | $379.50 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969189 |
| Principal investigator 1 | ModernaTX, Inc. | $950.00 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969193 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969195 |
| Principal investigator 1 | ModernaTX, Inc. | $200.58 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969197 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969203 |
| Principal investigator 1 | ModernaTX, Inc. | $3,520.80 | 06/11/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969207 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,200.50 | 06/11/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105948 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $50,190.94 | 06/10/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105936 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $72,059.50 | 06/10/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105943 |
| Principal investigator 1 | Janssen Research & Development, LLC | $792.00 | 06/09/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175195787 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,969.40 | 06/09/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105912 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,405.14 | 06/09/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105919 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $19,877.60 | 06/09/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105924 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $27,828.64 | 06/09/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105930 |
| Principal investigator 1 | ModernaTX, Inc. | $1,980.00 | 06/06/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969199 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 06/04/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968973 |
| Principal investigator 1 | ModernaTX, Inc. | $250.08 | 06/04/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968977 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,800.00 | 06/02/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105889 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $500.00 | 06/02/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125385 |
| Principal investigator 1 | ModernaTX, Inc. | $4,455.36 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968987 |
| Principal investigator 1 | ModernaTX, Inc. | $6,229.56 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969033 |
| Principal investigator 1 | ModernaTX, Inc. | $819.59 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969117 |
| Principal investigator 1 | ModernaTX, Inc. | $20,202.70 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969151 |
| Principal investigator 1 | ModernaTX, Inc. | $81,220.04 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005633 |
| Principal investigator 1 | ModernaTX, Inc. | $4,258.89 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005653 |
| Principal investigator 1 | ModernaTX, Inc. | $25,984.40 | 05/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005667 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,822.10 | 05/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215286 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $237,593.70 | 05/07/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105810 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $450.00 | 05/02/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105804 |
| Principal investigator 1 | ModernaTX, Inc. | $1,639.18 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969103 |
| Principal investigator 1 | ModernaTX, Inc. | $23,135.35 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969155 |
| Principal investigator 1 | ModernaTX, Inc. | $4,380.48 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969157 |
| Principal investigator 1 | ModernaTX, Inc. | $33,117.76 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005629 |
| Principal investigator 1 | ModernaTX, Inc. | $19,677.02 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005647 |
| Principal investigator 1 | ModernaTX, Inc. | $14,196.30 | 04/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005659 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $19,351.02 | 04/28/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105821 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,649.48 | 04/28/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105826 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,232.00 | 04/23/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175194441 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,239.30 | 04/21/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105815 |
| Principal investigator 1 | Bavarian Nordic A/S | $17,087.32 | 04/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215276 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,250.00 | 04/18/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215284 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 04/07/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969169 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,109.70 | 04/02/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215282 |
| Principal investigator 1 | Bavarian Nordic A/S | $16,723.92 | 04/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215274 |
| Principal investigator 1 | ModernaTX, Inc. | $221.00 | 04/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005657 |
| Principal investigator 1 | ModernaTX, Inc. | $264.00 | 04/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005661 |
| Principal investigator 1 | ModernaTX, Inc. | $14,807.00 | 03/28/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005651 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,468.80 | 03/28/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125421 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,183.59 | 03/28/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125448 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $15,840.00 | 03/26/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older | No dispute reported | 06/30/2026 | 1226105873 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $5,178.60 | 03/26/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105878 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $166,499.76 | 03/26/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105883 |
| Principal investigator 1 | ModernaTX, Inc. | $11,286.99 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969047 |
| Principal investigator 1 | ModernaTX, Inc. | $14,989.10 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969065 |
| Principal investigator 1 | ModernaTX, Inc. | $149.76 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969163 |
| Principal investigator 1 | ModernaTX, Inc. | $4,455.36 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969167 |
| Principal investigator 1 | ModernaTX, Inc. | $29,812.23 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005635 |
| Principal investigator 1 | ModernaTX, Inc. | $30,904.64 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005639 |
| Principal investigator 1 | ModernaTX, Inc. | $25,956.92 | 03/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005673 |
| Principal investigator 1 | Bavarian Nordic A/S | $700.00 | 03/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215266 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,944.39 | 03/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215268 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,506.00 | 03/21/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175195751 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $4,969.40 | 03/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105864 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $750.00 | 03/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105868 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150,885.72 | 03/20/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226104417 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $690.00 | 03/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125437 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,073.24 | 03/20/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125440 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $14,200.00 | 03/19/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105850 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $600.00 | 03/19/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105857 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 03/19/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226104400 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 03/19/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125427 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $31,674.00 | 03/17/2025 | Non-covered Recipient Entity Suncoast Research Associates | A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older | No dispute reported | 06/30/2026 | 1232933874 |
| Principal investigator 1 | Bavarian Nordic A/S | $400.00 | 03/14/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215272 |
| Principal investigator 1 | Janssen Research & Development, LLC | $572.00 | 03/14/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196260 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,419.78 | 03/14/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts | No dispute reported | 06/30/2026 | 1226105844 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $32,027.87 | 03/07/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125424 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,495.00 | 03/03/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175197248 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $2,316.60 | 03/03/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105831 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $679,006.01 | 03/03/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105838 |
| Principal investigator 1 | ModernaTX, Inc. | $40,130.09 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252968989 |
| Principal investigator 1 | ModernaTX, Inc. | $5,110.56 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969013 |
| Principal investigator 1 | ModernaTX, Inc. | $26,678.34 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969049 |
| Principal investigator 1 | ModernaTX, Inc. | $21,506.10 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969073 |
| Principal investigator 1 | ModernaTX, Inc. | $4,417.92 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969095 |
| Principal investigator 1 | ModernaTX, Inc. | $14,196.30 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005631 |
| Principal investigator 1 | ModernaTX, Inc. | $34,856.64 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005645 |
| Principal investigator 1 | ModernaTX, Inc. | $54,844.46 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005663 |
| Principal investigator 1 | ModernaTX, Inc. | $11,615.24 | 02/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005665 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,152.28 | 02/26/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215246 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,812.93 | 02/26/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215260 |
| Principal investigator 1 | Bavarian Nordic A/S | $270.84 | 02/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215252 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,200.00 | 02/21/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215270 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,705.00 | 02/19/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196163 |
| Principal investigator 1 | ModernaTX, Inc. | $243.00 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969015 |
| Principal investigator 1 | ModernaTX, Inc. | $94.50 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969021 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969023 |
| Principal investigator 1 | ModernaTX, Inc. | $67.50 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969143 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $156,764.72 | 02/19/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123758 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,603.00 | 02/14/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215248 |
| Principal investigator 1 | Bavarian Nordic A/S | $812.51 | 02/14/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215254 |
| Principal investigator 1 | Bavarian Nordic A/S | $14,199.53 | 02/14/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215256 |
| Principal investigator 1 | Bavarian Nordic A/S | $270.84 | 02/12/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215250 |
| Principal investigator 1 | Bavarian Nordic A/S | $260.30 | 02/12/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215258 |
| Principal investigator 1 | Bavarian Nordic A/S | $700.00 | 02/07/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215262 |
| Principal investigator 1 | Bavarian Nordic A/S | $609.55 | 02/07/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250215264 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,418.99 | 02/07/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226104413 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $179,344.80 | 02/03/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125432 |
| Principal investigator 1 | ModernaTX, Inc. | $6,296.94 | 01/30/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968975 |
| Principal investigator 1 | ModernaTX, Inc. | $8,720.00 | 01/29/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969205 |
| Principal investigator 1 | ModernaTX, Inc. | $4,800.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252968979 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252968981 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252969029 |
| Principal investigator 1 | ModernaTX, Inc. | $2,590.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252969031 |
| Principal investigator 1 | ModernaTX, Inc. | $819.59 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969041 |
| Principal investigator 1 | ModernaTX, Inc. | $8,146.25 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969067 |
| Principal investigator 1 | ModernaTX, Inc. | $52,760.34 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969087 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252969093 |
| Principal investigator 1 | ModernaTX, Inc. | $2,283.84 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969107 |
| Principal investigator 1 | ModernaTX, Inc. | $5,000.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252969145 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252969147 |
| Principal investigator 1 | ModernaTX, Inc. | $4,455.36 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969153 |
| Principal investigator 1 | ModernaTX, Inc. | $17,443.53 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969165 |
| Principal investigator 1 | ModernaTX, Inc. | $92,607.90 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969171 |
| Principal investigator 1 | ModernaTX, Inc. | $35,145.80 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005641 |
| Principal investigator 1 | ModernaTX, Inc. | $24,047.92 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005655 |
| Principal investigator 1 | ModernaTX, Inc. | $15,615.93 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005671 |
| Principal investigator 1 | ModernaTX, Inc. | $12,559.80 | 01/27/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005681 |
| Principal investigator 1 | ModernaTX, Inc. | $2,640.00 | 01/24/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252968959 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $600.00 | 01/23/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226104419 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 01/23/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226125444 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,195.00 | 01/22/2025 | Non-covered Recipient Entity Suncoast Rsrch Associates Llc | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175196954 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 01/22/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1252969191 |
| Principal investigator 1 | ModernaTX, Inc. | $29,867.76 | 01/22/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005669 |
| Principal investigator 1 | ModernaTX, Inc. | $68.30 | 01/20/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC | A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis | No dispute reported | 06/30/2026 | 1252969069 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $21,553.09 | 01/15/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH GROUP, LLC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185544475 |
| Principal investigator 1 | ModernaTX, Inc. | $13,500.00 | 01/08/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969129 |
| Principal investigator 1 | ModernaTX, Inc. | $8,177.00 | 01/08/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253005675 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $257,573.88 | 01/07/2025 | Non-covered Recipient Entity Suncoast Research Associates Llc | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226105798 |
| Principal investigator 1 | ModernaTX, Inc. | $6,750.00 | 01/06/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES LLC DBA SRA TRIALS | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252969079 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,608.57 | 01/03/2025 | Non-covered Recipient Entity Suncoast Research Associates, Llc | A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older | No dispute reported | 06/30/2026 | 1226104407 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $635,214.88 | 01/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124364 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $365,668.85 | 01/01/2025 | Non-covered Recipient Entity SUNCOAST RESEARCH ASSOCIATES | A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124946 |